TBTjerk Bueters

Tjerk Bueters

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tjerk Bueters has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Abbas M. Walji

    Merck & Co., Inc., West Point, USA

    1 shared publication
  • Adriaan P. Ijzerman

    Department of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Gorleaus Laboratory, Leiden University, Einsteinweg 55, P.O. Box 9502, 2300 RA Leiden, The Netherlands

    1 shared publication
  • An Bautmans

    MRL, Merck & Co., Inc., Rahway, NJ (D.G.J., L.-C.C., P.B., A.B., T.B., P.G.B., I.C., F.-X.D., R.M.G., E.D.G., Y.G., S.N.H., J.M.J., H.J., E.A.K., K.A.K., J.T.K., E.L., C.L.L., A.Y.H.L., L.L., A.G.N., E.A.O., S.A.S., D.A.T., T.J.T., P.V., K.v.D., D.G.W., A.X., T.Z., D.Z., S.Z., X.Z., H.J.Z., A.M.W., H.B.W.).

    1 shared publication
  • Andy Xu

    MRL, Merck & Co., Inc., Rahway, NJ (D.G.J., L.-C.C., P.B., A.B., T.B., P.G.B., I.C., F.-X.D., R.M.G., E.D.G., Y.G., S.N.H., J.M.J., H.J., E.A.K., K.A.K., J.T.K., E.L., C.L.L., A.Y.H.L., L.L., A.G.N., E.A.O., S.A.S., D.A.T., T.J.T., P.V., K.v.D., D.G.W., A.X., T.Z., D.Z., S.Z., X.Z., H.J.Z., A.M.W., H.B.W.).

    1 shared publication
  • Anilkumar G. Nair

    Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA

    1 shared publication
  • Anita Y.H. Lee

    MRL, Merck & Co., Inc., Rahway, NJ (D.G.J., L.-C.C., P.B., A.B., T.B., P.G.B., I.C., F.-X.D., R.M.G., E.D.G., Y.G., S.N.H., J.M.J., H.J., E.A.K., K.A.K., J.T.K., E.L., C.L.L., A.Y.H.L., L.L., A.G.N., E.A.O., S.A.S., D.A.T., T.J.T., P.V., K.v.D., D.G.W., A.X., T.Z., D.Z., S.Z., X.Z., H.J.Z., A.M.W., H.B.W.).

    1 shared publication

Latest Publications

  • Open Access

    A Phase 1 Study of MK ‐1942, a Negative Allosteric Modulator of mGluR2 , in Healthy Japanese to Flexibly Assess Factors Including CYP2C19 Phenotype

    by Chihiro Hasegawa, Yohei Doi, Tomona Hirano, Masayoshi Shirakawa, Saori Tsuchiya, Hiroyuki Yoshitsugu, Kenichi Furihata, Callie Miller, Sonal Singh, Tamara Cabalu, et al.

    MK‐1942 is a negative allosteric modulator of the metabotropic glutamate receptor 2 that was investigated for the treatment of Alzheimer's disease and depression. Nonclinical studies with recombinant human CYPs and genotyped human hepatocytes suggested that CYP2C19 is involved in the metabolism of MK‐1942. Given the high incidence of different CYP2C19 polymorphisms in the Japanese population, a Phase 1 single and multiple dose study in healthy Japanese participants provided an opportunity to determine the involvement of CYP2C19 phenotype on the clinical PK of MK‐1942. Also, since a first‐in‐human study in non‐Japanese showed a decrease in exposures after administration with high‐fat meal, we further tested an effect of low‐fat meal on PK in the Japan study. The study was designed with flexibility which enabled dose selection for the multiple dose panels, based on the totality of safety and PK data. Oral administration of single and multiple doses of MK‐1942 in Japanese participants was generally well tolerated. AUC 0‐inf was comparable between fasted and fed (low‐fat meal) state. Following a single dose of MK‐1942, AUC 0‐inf was ~70% increased in CYP2C19 poor metabolizer (PM) vs. extensive metabolizer (EM). Therefore, a decision was made to test the multiple dose separately for each CYP2C19 phenotype, rather than grouping them into a single panel. As opposed to the expectation from the single dose result, steady state exposures were similar among CYP2C19 phenotypes. These data supported the subsequent global Phase 2 study to permit a low‐fat meal around dosing and no dose adjustment for any CYP2C19 phenotype.

  • Open Access

    Drug–Drug Interaction Risk Assessment Strategies for Biologics in Inflammatory Bowel Disease: A Literature‐Based Evidence Mini‐Review

    by Claire Steinbronn, Susan E. Stanley, Tjerk Bueters, Sihem Ait‐Oudhia

    Biologic therapies are traditionally regarded as having low potential for drug–drug interactions (DDIs) due to their large molecular size and limited direct involvement with drug‐metabolizing enzymes and transporters (DMETs). However, accumulating evidence indicates that these drug products may indirectly modulate DMET activity through cytokine‐mediated mechanisms, particularly in the context of inflammatory diseases. Pro‐inflammatory cytokines such as interleukin‐6 have been shown to suppress the expression of cytochrome P450 (CYP) enzymes in vitro, most notably CYP3A4, thereby potentially altering the metabolic clearance of concomitant medications. This phenomenon may be pertinent in conditions such as inflammatory bowel disease (IBD) where chronic inflammation and systemic physiological alterations may significantly influence drug disposition. Although the U.S. Food and Drug Administration provides a decision framework to assess large molecule DDI risk based on the mechanism of action, it does not offer a standardized, mechanistic approach for evaluating such interactions. In response, alternative methodologies such as the use of endogenous biomarkers like 4β‐hydroxycholesterol, a proposed surrogate for CYP3A activity, and pharmacokinetic modeling are in exploration to support DDI risk assessment to potentially avoid dedicated clinical trials in patients. This review evaluates current knowledge on biologics‐mediated DDIs with a particular focus on drug‐disease interactions in IBD. There is an opportunity for a more structured, mechanistically informed evaluation that integrates cytokine profiling and biomarker‐based approaches to identify DDI risk and enhance the overall understanding of the degree of interaction and its clinical significance.

  • Top Cited Papers
    Open Access

    Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

    by Douglas G. Johns, Louis-Charles Campeau, Puja Banka, An Bautmans, Tjerk Bueters, Elisabetta Bianchi, Danila Branca, Paul G. Bulger, Inne Crevecoeur, Fa-Xiang Ding, et al.

    Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design. Methods: Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol). Results: MK-0616 displayed high affinity ( K i = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84–103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple–oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43–85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616. Conclusions: This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.


  • Can quantitative pharmacology improve productivity in pharmaceutical research and development?

    by Mayankbhai Patel, Tjerk Bueters

    (2020). Can quantitative pharmacology improve productivity in pharmaceutical research and development?. Expert Opinion on Drug Discovery. Ahead of Print.


  • Optimization of Human Dose Prediction by Using Quantitative and Translational Pharmacology in Drug Discovery

    by Tjerk Bueters, Christopher Gibson, Sandra A G Visser

    In this perspective article, we explain how quantitative and translational pharmacology, when well-implemented, is believed to lead to improved clinical candidates and drug targets that are differentiated from current treatment options. Quantitative and translational pharmacology aims to build and continuously improve the quantitative relationship between drug exposure, target engagement, efficacy, safety and its interspecies relationship at every phase of drug discovery. Drug hunters should consider and apply these concepts to develop compounds with a higher probability of interrogating the clinical biological hypothesis. We offer different approaches to set an initial effective concentration or pharmacokinetic–pharmacodynamic target in man and to predict human pharmacokinetics that determine together the predicted human dose and dose schedule. All concepts are illustrated with ample literature examples.


  • Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human

    by Tjerk Bueters, Sanja Juric, Anna-Karin Sohlenius-Sternbeck, Yin Hu, Johan Bylund

    1. Intestinal loss, 1 − (Fobs/fH), is the missing fraction of the dose that is unexplained by systemic clearance. Here, we investigated whether intestinal loss in rat is predictive for human, and whether intestinal metabolism explained observed differences between rat and human. 2. For 81 marketed drugs, human and rat intestinal loss values were calculated from the literature and in-house sources. To examine the contribution of intestinal cytochrome P450-mediated metabolism to the high observed intestinal loss in the rat, metabolism was determined in rat and human intestinal microsomes for 15 compounds. 3. Oral bioavailability poorly correlated between rat and human. Twenty-two compounds in the human and 47 compounds in the rat showed an intestinal loss of more than 20%. The intestinal availability for many compounds was higher in human than in rat. Selected compounds, however, were more stable in rat than in human intestinal microsomes. 4. The rat poorly predicts the risk for intestinal loss in human; many compounds in rat had lower bioavailability than anticipated based on the hepatic clearance, but demonstrated little intestinal loss in human. This discrepancy appeared not to be caused by a higher cytochrome P450-mediated intestinal metabolism in the rat.


  • Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action

    by Tjerk J.H. Bueters, Herman P.M. van Helden, Adriaan P. Ijzerman, Meindert Danhof